|
1
|
Ruiz-Ortega M, Rayego-Mateos S, Lamas S,
Ortiz A and Rodrigues-Diez RR: Targeting the progression of chronic
kidney disease. Nat Rev Nephrol. 16:269–288. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Panizo S, Martinez-Arias L, Alonso-Montes
C, Cannata P, Martín-Carro B, Fernández-Martín JL, Naves-Díaz M,
Carrillo-López N and Cannata-Andía JB: Fibrosis in chronic kidney
disease: Pathogenesis and consequences. Int J Mol Sci. 22:4082021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu Y: Cellular and molecular mechanisms
of renal fibrosis. Nat Rev Nephrol. 7:684–696. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yuan Q and Liu YH: Recent advances on
understanding of the cellular and molecular mechisms of renal
fibrosis. J Anhui Univ Nat Sci Ed. 42:115–124. 2018.(In
Chinese).
|
|
5
|
Li R, Guo Y, Zhang Y, Zhang X, Zhu L and
Yan T: Salidroside ameliorates renal interstitial fibrosis by
inhibiting the TLR4/NF-κB and MAPK signaling pathways. Int J Mol
Sci. 20:11032019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Simões e Silva AC, Silveira KD, Ferreira
AJ and Teixeira MM: ACE2, angiotensin-(1–7) and Mas receptor axis
in inflammation and fibrosis. Br J Pharmacol. 169:477–492. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang M and Zhang S: T cells in fibrosis
and fibrotic diseases. Front Immunol. 11:11422020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tang PMK, Nikolic-Paterson DJ and Lan HY:
Macrophages: Versatile players in renal inflammation and fibrosis.
Nat Rev Nephrol. 15:144–158. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu L, Kou P, Zeng Q, Pei G, Li Y, Liang
H, Xu G and Chen S: CD4+ T lymphocytes, especially Th2 cells,
contribute to the progress of renal fibrosis. Am J Nephrol.
36:386–396. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lech M, Gröbmayr R, Ryu M, Lorenz G,
Hartter I, Mulay SR, Susanti HE, Kobayashi KS, Flavell RA and
Anders HJ: Macrophage phenotype controls long-term AKI
outcomes-kidney regeneration versus atrophy. J Am Soc Nephrol.
25:292–304. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tao X, Yin L, Xu L and Peng J: Dioscin: A
diverse acting natural compound with therapeutic potential in
metabolic diseases, cancer, inflammation and infections. Pharmacol
Res. 137:259–269. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Duan H, Zhang Q, Liu J, Li R, Wang D, Peng
W and Wu C: Suppression of apoptosis in vascular endothelial cell,
the promising way for natural medicines to treat atherosclerosis.
Pharmacol Res. 168:1055992021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang D and Wang X: Diosgenin and its
analogs: Potential protective agents against atherosclerosis. Drug
Des Devel Ther. 16:2305–2323. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Passos FRS, Araújo-Filho HG, Monteiro BS,
Shanmugam S, Araújo AAS, Almeida JRGDS, Thangaraj P, Júnior LJQ and
Quintans JSS: Anti-inflammatory and modulatory effects of steroidal
saponins and sapogenins on cytokines: A review of pre-clinical
research. Phytomedicine. 96:1538422022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gu L, Tao X, Xu Y, Han X, Qi Y, Xu L, Yin
L and Peng J: Dioscin alleviates BDL- and DMN-induced hepatic
fibrosis via Sirt1/Nrf2-mediated inhibition of p38 MAPK pathway.
Toxicol Appl Pharmacol. 292:19–29. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu H, Lin L, Zhang Z, Zhang H and Hu H:
Targeting NF-κB pathway for the therapy of diseases: Mechanism and
clinical study. Signal Transduct Target Ther. 5:2092020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Qiao Y, Xu L, Tao X, Yin L, Qi Y, Xu Y,
Han X, Tang Z, Ma X, Liu K and Peng J: Protective effects of
dioscin against fructose-induced renal damage via adjusting
Sirt3-mediated oxidative stress, fibrosis, lipid metabolism and
inflammation. Toxicol Lett. 284:37–45. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cao D, Wang Y, Zhang Y, Zhang Y, Huang Q,
Yin Z, Cai G, Chen X and Sun X: Regulation of connective tissue
growth factor expression by miR-133b for the treatment of renal
interstitial fibrosis in aged mice with unilateral ureteral
obstruction. Stem Cell Res Ther. 12:1712021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gu L, Wang Y, Yang G, Tilyek A, Zhang C,
Li S, Yu B, Chai C and Cao Z: Ribes diacanthum Pall (RDP)
ameliorates UUO-induced renal fibrosis via both canonical and
non-canonical TGF-β signaling pathways in mice. J Ethnopharmacol.
231:302–310. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hosseinian S, Rad AK, Bideskan AE,
Soukhtanloo M, Sadeghnia H, Shafei MN, Motejadded F, Mohebbati R,
Shahraki S and Beheshti F: Thymoquinone ameliorates renal damage in
unilateral ureteral obstruction in rats. Pharmacol Rep. 69:648–657.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
El-Abhar H, Abd El Fattah MA, Wadie W and
El-Tanbouly DM: Cilostazol disrupts TLR-4, Akt/GSK-3β/CREB, and
IL-6/JAK-2/STAT-3/SOCS-3 crosstalk in a rat model of Huntington's
disease. PLoS One. 13:e2038372018. View Article : Google Scholar
|
|
22
|
Liu S, Chen X, Zhang S, Wang X, Du X, Chen
J and Zhou G: miR-106b-5p targeting SIX1 inhibits TGF-β1-induced
pulmonary fibrosis and epithelial-mesenchymal transition in asthma
through regulation of E2F1. Int J Mol Med. 47:048552021. View Article : Google Scholar
|
|
23
|
Okarmus J, Bogetofte H, Schmidt SI, Ryding
M, García-López S, Ryan BJ, Martínez-Serrano A, Hyttel P and Meyer
M: Lysosomal perturbations in human dopaminergic neurons derived
from induced pluripotent stem cells with PARK2 mutation. Sci Rep.
10:102782020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yamaguchi J, Tanaka T and Nangaku M:
Recent advances in understanding of chronic kidney disease.
F1000Res. 4:12122015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vernon MA, Mylonas KJ and Hughes J:
Macrophages and renal fibrosis. Semin Nephrol. 30:302–317. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wada T, Furuichi K, Sakai N, Iwata Y,
Kitagawa K, Ishida Y, Kondo T, Hashimoto H, Ishiwata Y, Mukaida N,
et al: Gene therapy via blockade of monocyte chemoattractant
protein-1 for renal fibrosis. J Am Soc Nephrol. 15:940–948. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liao Y, Tan RZ, Li JC, Liu TT, Zhong X,
Yan Y, Yang JK, Lin X, Fan JM and Wang L: Isoliquiritigenin
attenuates UUO-induced renal inflammation and fibrosis by
inhibiting mincle/Syk/NF-kappa B signaling pathway. Drug Des Devel
Ther. 14:1455–1468. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhong Y, Liu J, Sun D, Guo T, Yao Y, Xia
X, Shi C and Peng X: Dioscin relieves diabetic nephropathy via
suppressing oxidative stress and apoptosis, and improving
mitochondrial quality and quantity control. Food Funct.
13:3660–3673. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cai S, Chen J and Li Y: Dioscin protects
against diabetic nephropathy by inhibiting renal inflammation
through TLR4/NF-κB pathway in mice. Immunobiology. 225:1519412020.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang Y, Xu Y, Qi Y, Xu L, Song S, Yin L,
Tao X, Zhen Y, Han X, Ma X, et al: Protective effects of dioscin
against doxorubicin-induced nephrotoxicity via adjusting
FXR-mediated oxidative stress and inflammation. Toxicology.
378:53–64. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang Y, Tao X, Yin L, Xu L, Xu Y, Qi Y,
Han X, Song S, Zhao Y, Lin Y, et al: Protective effects of dioscin
against cisplatin-induced nephrotoxicity via the
microRNA-34a/sirtuin 1 signalling pathway. Br J Pharmacol.
174:2512–2527. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mankan AK, Lawless MW, Gray SG, Kelleher D
and McManus R: NF-kappaB regulation: The nuclear response. J Cell
Mol Med. 13:631–643. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mitchell S, Vargas J and Hoffmann A:
Signaling via the NFκB system. Wiley Interdiscip Rev Syst Biol Med.
8:227–241. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hirano T: IL-6 in inflammation,
autoimmunity and cancer. Int Immunol. 33:127–148. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zusso M, Lunardi V, Franceschini D,
Pagetta A, Lo R, Stifani S, Frigo AC, Giusti P and Moro S:
Ciprofloxacin and levofloxacin attenuate microglia inflammatory
response via TLR4/NF-kB pathway. J Neuroinflammation. 16:1482019.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kelley N, Jeltema D, Duan Y and He Y: The
NLRP3 inflammasome: An overview of mechanisms of activation and
regulation. Int J Mol Sci. 20:33282019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Black LM, Lever JM and Agarwal A: Renal
inflammation and fibrosis: A double-edged sword. J Histochem
Cytochem. 67:663–681. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bianconi V, Sahebkar A, Atkin SL and Pirro
M: The regulation and importance of monocyte chemoattractant
protein-1. Curr Opin Hematol. 25:44–51. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Du Y, Zhang H, Guo Y, Song K, Zeng L, Chen
Y, Xie Z and Li R: CD38 deficiency up-regulated IL-1β and MCP-1
through TLR4/ERK/NF-κB pathway in sepsis pulmonary injury. Microbes
Infect. 23:1048452021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Afonina IS, Zhong Z, Karin M and Beyaert
R: Limiting inflammation-the negative regulation of NF-κB and the
NLRP3 inflammasome. Nat Immunol. 18:861–869. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang WJ, Chen SJ, Zhou SC, Wu SZ and Wang
H: Inflammasomes and fibrosis. Front Immunol. 12:6431492021.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Otto G: IL-1β switches on kidney fibrosis.
Nat Rev Nephrol. 14:4752018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Klinkhammer BM, Floege J and Boor P: PDGF
in organ fibrosis. Mol Aspects Med. 62:44–62. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hayashi N, Yoshimoto T, Izuhara K, Matsui
K, Tanaka T and Nakanishi K: T helper 1 cells stimulated with
ovalbumin and IL-18 induce airway hyperresponsiveness and lung
fibrosis by IFN-gamma and IL-13 production. Proc Natl Acad Sci USA.
104:14765–14770. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liang H, Xu F, Zhang T, Huang J, Guan Q,
Wang H and Huang Q: Inhibition of IL-18 reduces renal fibrosis
after ischemia-reperfusion. Biomed Pharmacother. 106:879–889. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhao W, Ma L, Cai C and Gong X: Caffeine
inhibits NLRP3 inflammasome activation by suppressing MAPK/NF-κB
and A2aR signaling in LPS-induced THP-1 macrophages. Int J Biol
Sci. 15:1571–1581. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wen Y, Lu X, Ren J, Privratsky JR, Yang B,
Rudemiller NP, Zhang J, Griffiths R, Jain MK, Nedospasov SA, et al:
KLF4 in macrophages attenuates TNFα-mediated kidney injury and
fibrosis. J Am Soc Nephrol. 30:1925–1938. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang L, Xie J, Gan R, Wu Z, Luo H, Chen
X, Lu Y, Wu L and Zheng D: Synergistic inhibition of lung cancer
cells by EGCG and NF-κB inhibitor BAY11-7082. J Cancer.
10:6543–6556. 2019. View Article : Google Scholar : PubMed/NCBI
|
